The SHIfT study (Systolic Heart failure treatment with If inhibitor ivabradine Trial) was designed to evaluate the effect of ivabradine in addition to guidelines-based treatment on cardiovascular outcomes, symptoms, and quality of life in patients with chronic heart failure and left ventricular systolic dysfunction.1
- Resting heart rate has an independent prognostic value in patients with chronic heart failure
- Reducing heart rate is associated with reduction in morbidity-mortality in chronic heart failure
- Ivabradine has a unique pharmacodynamic profile: heart rate reduction without any deleterious impact on hemodynamics
- Ivabradine has beneficial effects on cardiac remodeling, capillary density, and left ventricular dysfunction.
Rationale for benefits of ivabradine in heart failure
1. Swedberg K, et al. Eur J Heart Fail. 2010;12(1):75-81.